Epidemiology of non-alcoholic fatty liver disease
- PMID: 20460905
- DOI: 10.1159/000282080
Epidemiology of non-alcoholic fatty liver disease
Abstract
Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide. The prevalence of NAFLD in the general population of Western countries is 20-30%. About 2-3% of the general population is estimated to have non-alcoholic steatohepatitis (NASH), which may progress to liver cirrhosis and hepatocarcinoma. As a rule, the prevalence of NAFLD is higher in males and increases with increasing age, and it is influenced by the diagnostic method and the characteristics of the population, especially lifestyle habits. Population-based studies provide better estimates of the prevalence of NAFLD as compared to autoptic and clinical studies, but few such studies have been performed to date. The diagnosis of NAFLD in population studies is usually obtained by ultrasonography, which is known to underestimate the prevalence of fatty liver. The Dallas Heart Study and the Dionysos Study reported that 30% of the adults in the USA and 25% in Italy have NAFLD. In these studies, 79% and 55% of patients with NAFLD had normal aminotransferase levels, showing that liver enzymes are not surrogate markers of NAFLD in the general population. Noninvasive markers such as the fatty liver index obtained from the Dionysos Study may be useful to screen for NAFLD in the general population. The most important risk factors for NAFLD are male gender, age, obesity, insulin resistance and the cardiometabolic alterations that define the metabolic syndrome. The prevalence of NAFLD is 80-90% in obese adults, 30-50% in patients with diabetes and up to 90% in patients with hyperlipidemia. The prevalence of NAFLD among children is 3-10%, rising up to 40-70% among obese children. Moreover, pediatric NAFLD increased from about 3% a decade ago to 5% today, with a male-to-female ratio of 2:1. The incidence and natural history of NAFLD are still not well defined, but it is recognized that the majority of individuals with NAFLD do not develop NASH. The incidence of NAFLD is probably increasing in Western countries, strictly linked to lifestyle habits.
Copyright 2010 S. Karger AG, Basel.
Similar articles
-
What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?J Gastroenterol Hepatol. 2007 Jun;22(6):794-800. doi: 10.1111/j.1440-1746.2007.04952.x. Epub 2007 May 13. J Gastroenterol Hepatol. 2007. PMID: 17498218
-
The epidemiology of nonalcoholic fatty liver disease in adults.J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S5-10. doi: 10.1097/01.mcg.0000168638.84840.ff. J Clin Gastroenterol. 2006. PMID: 16540768 Review.
-
Non-alcoholic fatty liver disease--a common and benign finding in octogenarian patients.Liver Int. 2004 Dec;24(6):588-94. doi: 10.1111/j.1478-3231.2004.0969.x. Liver Int. 2004. PMID: 15566509
-
Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study.Hepatology. 2005 Jul;42(1):44-52. doi: 10.1002/hep.20734. Hepatology. 2005. PMID: 15895401
-
[Non-alcoholic fatty liver disease--new view].Pol Merkur Lekarski. 2008 Jun;24(144):568-71. Pol Merkur Lekarski. 2008. PMID: 18702346 Review. Polish.
Cited by
-
Altered hepatic lipid metabolism contributes to nonalcoholic fatty liver disease in leptin-deficient Ob/Ob mice.J Obes. 2013;2013:296537. doi: 10.1155/2013/296537. Epub 2013 Jan 16. J Obes. 2013. PMID: 23401753 Free PMC article.
-
Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways.Clin Sci (Lond). 2022 Sep 30;136(18):1347-1366. doi: 10.1042/CS20220572. Clin Sci (Lond). 2022. PMID: 36148775 Free PMC article. Review.
-
A Computational Model of Hepatic Energy Metabolism: Understanding Zonated Damage and Steatosis in NAFLD.PLoS Comput Biol. 2016 Sep 15;12(9):e1005105. doi: 10.1371/journal.pcbi.1005105. eCollection 2016 Sep. PLoS Comput Biol. 2016. PMID: 27632189 Free PMC article.
-
Insulin-like growth factor binding protein 3 promoter variant (rs2854744) is associated with nonalcoholic fatty liver disease.Arch Endocrinol Metab. 2023 Nov 10;68:e230017. doi: 10.20945/2359-4292-2023-0017. Arch Endocrinol Metab. 2023. PMID: 37948568 Free PMC article.
-
Ramadan Fasting in Individuals with Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Transplant, and Bariatric Surgery: A Narrative Review.J Clin Med. 2024 Jul 2;13(13):3893. doi: 10.3390/jcm13133893. J Clin Med. 2024. PMID: 38999457 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials